Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment (CHIPOR)
A Phase III Randomized Study Evaluating Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in the Treatment of Relapse Ovarian Cancer
Sponsor: UNICANCER
A PHASE3 clinical study on Ovarian Epithelial Cancer Recurrent, this trial is ongoing. The trial is conducted by UNICANCER and has accumulated 14 data snapshots since 2011. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Active Not Recruiting PHASE3
-
May 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE3
-
Sep 2024 — May 2025 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
May 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
▶ Show 9 earlier versions
-
May 2023 — May 2024 [monthly]
Active Not Recruiting PHASE3
-
Feb 2023 — May 2023 [monthly]
Active Not Recruiting PHASE3
-
Jun 2022 — Feb 2023 [monthly]
Active Not Recruiting PHASE3
-
Jun 2021 — Jun 2022 [monthly]
Active Not Recruiting PHASE3
Status: Suspended → Active Not Recruiting
-
Jan 2021 — Jun 2021 [monthly]
Suspended PHASE3
-
May 2020 — Jan 2021 [monthly]
Suspended PHASE3
Status: Recruiting → Suspended
-
Apr 2019 — May 2020 [monthly]
Recruiting PHASE3
-
Jun 2018 — Apr 2019 [monthly]
Recruiting PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE3
First recorded
Apr 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- UNICANCER
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amiens, France , Angers, France , Badalona, Spain , Bordeaux, France , Brest, France , Brussels, Belgium , Caen, France , Clermont-Ferrand, France , Dijon, France , Grenoble, France and 15 more locations